The DEAD-box RNA helicases p68 (DDX5) and p72 (DDX17) have been shown to act as transcriptional coactivators for a diverse range of transcription factors, including oestrogen receptor-a (ERa). Here, we show that, although both proteins interact with and co-activate ERa in reporter gene assays, small interfering RNA-mediated knockdown of p72, but not p68, results in a significant inhibition of oestrogen-dependent transcription of endogenous ERa-responsive genes and oestrogen-dependent growth of MCF-7 and ZR75-1 breast cancer cells. Furthermore, immunohistochemical staining of ERa-positive primary breast cancers for p68 and p72 indicate that p72 expression is associated with an increased period of relapse-free and overall survival (P ¼ 0.006 and 0.016, respectively), as well as being inversely associated with Her2 expression (P ¼ 0.008). Conversely, p68 shows no association with relapse-free period, or overall survival, but it is associated with an increased expression of Her2 (P ¼ 0.001), AIB-1 (Po0.001) and higher tumour grade (P ¼ 0.044). Our data thus highlight a crucial role for p72 in ERa co-activation and oestrogen-dependent cell growth and provide evidence in support of distinct but important roles for both p68 and p72 in regulating ERa activity in breast cancer.
Introduction
The DEAD-box subfamily of RNA helicases, originally so named on the basis of the presence of a conserved motif having the sequence Asp-Glu-Ala-Asp, have been implicated in cellular processes involving the regulation of RNA structure, including pre-mRNA processing, RNA export, RNA degradation, ribosome assembly, translation and miRNA maturation (Linder et al., 1989; Tanner and Linder, 2001; Fuller-Pace, 2006) . The p68 RNA helicase (DDX5) and the closely related p72 RNA helicase (DDX17) are two key members of the DEADbox RNA helicases that are essential for viability; p68À/À mice die in utero and p72À/À mice die shortly after birth, with mice for both knockouts exhibiting severe developmental defects (Fukuda et al., 2007) .
Recent findings have shown that p68 and p72 act as transcriptional co-regulators required for the action of diverse transcription factors. Evidence for this was first forthcoming through the demonstration that p68 associates with oestrogen receptor-a (ERa), with preferential interaction being observed for ERa phosphorylated at serine 118 (Endoh et al., 1999) . p72 has also been shown to be an ERa co-activator (Watanabe et al., 2001) . p68 also acts as a transcriptional co-activator of the ERa-related androgen receptor (Clark et al., 2008) , the tumour suppressor p53 (Bates et al., 2005) and Runx2, a regulator of osteoblast differentiation (Jensen et al., 2008) . Both p68 and p72 have also been shown to co-activate MyoD, acting as regulators of muscle differentiation (Caretti et al., 2006) . Although the mechanisms of p68 and p72 action as transcriptional co-activators remain to be defined, their interaction with other co-activators, including the histone acetyltransferases, CBP/p300 and P/CAF (Rossow and Janknecht, 2003; Shin and Janknecht, 2007) , and the steroid receptor co-activator (SRC) family of nuclear receptor co-activators (Watanabe et al., 2001) , which themselves interact with CBP/p300 and P/CAF (Goodman and Smolik, 2000) , is suggestive of roles for p68 and p72 in the regulation of histone modification by histone acetyltransferases. A potential role for the RNA binding/helicase activity of p68/p72 has been suggested by the finding that they co-immunoprecipitate with ERa, SRC and the RNA co-activator SRA (Watanabe et al., 2001) , although RNA helicase activity per se does not appear to be required for co-activation in reporter assays (Endoh et al., 1999) . Finally, p68 and p72 also have potential as co-repressors through association with histone deacetylase HDAC1 (Wilson et al., 2004) , the association being promoted by sumoylation of p68 (Jacobs et al., 2007) .
Expression of ERa is one of the key features of breast cancer, the most frequently observed cancer in women in industrialized nations, with ERa expression being found in approximately 70% of tumours. Its presence is both prognostic and predictive of response to endocrine therapies. Determination of ER status of tumours is therefore crucial in the management of ER-positive breast cancers by treatment with endocrine agents, such as tamoxifen, that inhibit ERa activity (Ali and Coombes, 2002) , or aromatase inhibitors that reduce the levels of circulating estrogens. However, following an initial response to tamoxifen, a significant proportion of patients relapse. These tumours often remain ERa positive and may respond to an alternative endocrine agent, showing ERa-dependence for the continued growth of these tumours (Buzdar and Howell, 2001; Morris and Wakeling, 2002) , and indicating altered ERa function as a possible mechanism underlying treatment failure.
Oestrogen receptor-a is a member of the nuclear receptor superfamily of ligand-activated transcription factors (Mangelsdorf et al., 1995) . Activation of gene expression by ERa is mediated by two transcription activation domains, AF1 and AF2, which act in a promoter-and cell-specific manner. AF1, located N-terminal to the DNA-binding domain (DBD), functions in a ligand-independent manner and its activity can be stimulated through growth factor-regulated signalling cascades in the absence of oestrogen (Bunone et al., 1996) . AF1 activity is enhanced by activating phosphorylation of serines 104, 106 and 118 through the mitogen-activated protein kinase (MAPK) pathway (Ali et al., 1993; Le Goff et al., 1994; Thomas et al., 2008) , and by cyclin-dependent protein kinases CDK2 (Ser-104/Ser106) (Trowbridge et al., 1997) and CDK7 (Ser-118) (Chen et al., 2000) . In addition, these phosphorylation sites are substrates for GSK-3 (Medunjanin et al., 2005; Grisouard et al., 2007) . AF2 is integral to the ligand-binding domain and its activity requires oestrogen binding by the ligand-binding domain, which results in a conformational change facilitating co-regulator recruitment (Glass, 1994) .
Transcriptional regulation by ERa requires the action of a plethora of transcriptional co-regulators at oestrogen-responsive gene promoters, which mediate chromatin remodelling (reviewed by Klinge, (2000) ). Extensive chromatin immunoprecipitation analysis of model oestrogen-responsive genes, in particular the pS2 gene, has shown that these co-regulators are recruited and dissociated in an ordered, cyclical manner, where the promoter is initially activated to produce one round of transcribed mRNA, then is reset to an inactive state before the next cycle of transcription begins (Shang et al., 2000; Metivier et al., 2003) . In the cycles of coregulator recruitment, p68 is one of the earliest ERa coactivators to be recruited, suggestive of a particularly important role for p68 in the regulation of oestrogenresponsive gene expression.
In this study, we have characterized further the importance of p68 and p72 in gene regulation by ERa, in particular using RNA interference-mediated downregulation of p68 and p72 in the MCF-7 breast cancer cell line. Furthermore, we have investigated the expression of both proteins in a cohort of human breast cancers and correlated their expression with a number of prognostic markers. These studies have identified p72 as a key factor in the regulation of oestrogen-dependent cell growth and have identified associations with improved patient survival, indicating that it has an important role in breast cancer pathogenesis.
Results
p68 and p72 co-activate ERa in synergy with SRC-1 To examine p68/p72 co-activator function, we transfected COS-1 cells with an oestrogen-responsive firefly luciferase reporter plasmid and combinations of full-length ERa or mutants lacking either AF1 or AF2 (Figure 1a) , together with p68, p72 and the well-characterized steroid receptor co-activator SRC-1. In agreement with previous reports (Endoh et al., 1999; Watanabe et al., 2001) , ERa activity was stimulated by co-transfection with p68 and p72 ( Figure 1b) ; this co-activation was synergistically enhanced by SRC-1. As has also previously been described (Endoh et al., 1999) , the RNA helicase activity of p68 is dispensable as co-transfection with a helicase-inactive p68 mutant did not prevent the stimulation of ERa activity by p68 (Figure 1c) , nor was co-activation of ERa blocked by a similar mutation in p72. p68 was originally identified as an ERa co-activator following in vitro purification of proteins that interacted preferentially with ERa phosphorylated at ser-118 by MAPK (Endoh et al., 1999) . In reporter assays using truncated ERa lacking the ligand-binding domain/AF2, p68 and p72 stimulated AF1 activity (Figure 1d ). Although mutation of Ser-104 or Ser-106 did not prevent co-activation by p68 or by p72, mutation of Ser-118 gave little or no stimulation of ERa activity by p68 and p72, with mutation of all three residues completely preventing co-activation of AF1 by p68 and p72. Interestingly, however, both p68 and p72 stimulated the activity of an ERa deletion mutant lacking AF1 (Figure 1e ), suggesting that co-activation of ERa by p68/p72 involves the ERa DBD and/or AF2, in addition to AF1. Again this co-activation was synergistically enhanced by SRC-1.
p68 and p72 interact with ERa in vitro and in vivo in an oestrogen-independent manner Using glutathione S-transferase (GST)-pulldowns, an in vitro interaction between ERa and p68 was observed, p68, p72, ERa co-activation and breast cancer NC Wortham et al the interaction being oestrogen independent ( Figure 2a ). Interestingly, deletion mutants lacking AF1 or AF2 interacted with p68, although only weak interactions were observed for AF1 or AF2, indicative of interaction of p68 and p72 with ERa DBD. Similar results were obtained for p72, although interaction with the mutant lacking AF1 was weaker than that for p68, indicating that the interaction of p68 and p72 with ERa is similar, at least in vitro. The lack of interaction between ERa-AF1 and p68/p72 could be due to a requirement for AF1 phosphorylation. However, interaction of AF1-DBD (ERa-DAF2) and the AF1 region with p68 and p72 was unaffected by mutation of S118 or of S104/ S106/S118 ( Figure 2b ). Nor was interaction between these ERa mutants and p68 or p72 stimulated by in vitro phosphorylation with ERK2 MAPK (Figure 2c ). Taken together, these findings show that regions in addition to the AF1 are important for the interaction between ERa and p68/p72 and indicate that the ERa DBD is likely to be important for interaction of ERa with p68 and p72. Co-immunoprecipitation of nuclear extracts prepared from MCF-7 cells treated with 10 nM oestrogen for 6 h showed that p68 and p72 co-immunoprecipitated with ERa in an oestrogen-independent manner ( Figure 2d ). Furthermore, we found that although ERa co-immunoprecipitated both p68 and p72, p68 co-immunoprecipitated ERa efficiently, but only co-immunoprecipitated a very small amount of p72, implying that ERa-p68 and ERa-p72 complexes may be distinct within the cell.
RNAi-mediated knockdown of p68 and p72 indicates that p72 is required for the expression of oestrogen-regulated genes To determine whether p68 and p72 are required for the expression of endogenous oestrogen-responsive genes, we knocked down the expression of these proteins by transfection of specific small interfering RNA (siRNA) molecules, which have previously been described (Bates et al., 2005) . Knockdown of p72 resulted in significantly reduced pS2 expression at both the mRNA and protein levels (Figures 3a and e) . For cathepsin D, knockdown of p72 led to a significant decrease in protein expression, although there was only a small, but reproducible, decrease in mRNA levels (Figures 3b and e) . Surprisingly, p68 knockdown did not affect pS2 or cathepsin D expression (Figures 3a,b and e). Knockdown of p68, p72, ERa co-activation and breast cancer NC Wortham et al p68 and p72 was confirmed by quantitative reverse transcription-PCR and western blotting (Figures 3c and  d) . Interestingly, we still observed oestrogen stimulation of pS2 and cathepsin D expression following p72 knockdown, although the overall level is markedly reduced, suggesting that p68 or other ERa co-regulators can compensate for p72, at least in part.
RNAi depletion of p72 inhibits the oestrogen-dependent growth of cells As p72 appears to be important for stimulation of oestrogen-regulated gene expression, we determined the effect of p68 or p72 knockdown on oestrogen-stimulated growth of MCF-7 cells. Although knockdown of p68 had no significant effect on cell growth compared with a non-silencing siRNA (Figure 4a ), knockdown of p72 (Figure 4b ) significantly reduced cell growth. To test whether the effects of p72 were oestrogen-specific, we treated these cells with 4-hydroxytamoxifen alone or in combination with oestrogen. We found that tamoxifen treatment does not further slow the growth of the cells, suggesting that the inhibition of MCF-7 cell growth following p72 knockdown is due to the inhibition of ERa activity (Figure 4c ). For all experiments, knockdown of p68 and p72 was confirmed by western blotting. Knockdown of p72 in ZR75-1 cells similarly inhibited oestrogen-stimulated growth, indicating that p72 is also required for ER function in these cells ( Supplementary  Figure 1) . Glutathione S-transferases (GST)-pulldown assays were carried out using 35 S-labelled, in vitro-translated p68 and p72 and GST-fusions of full-length ERa or regions of ERa, as shown. Double bands are observed for p68 and p72 (marked *); these are the result of internal translation initiation. Full-length (upper band) and N-terminal truncated forms of p68 and p72 are indicated. (c) GST-ERa-DAF2 and GST-ERa-AF1 were phosphorylated in vitro with ERK2 following pulldown using glutathione beads. In vitro-transcribed/translated p68 or p72 were then added and pulldowns completed as above. Western blotting with an ERa-phospho-S118-specific antibody shows phosphorylation of the GST-tagged proteins. (d) Co-immunoprecipitation of p68 and p72 with ERa. Nuclear extracts were prepared from MCF-7 cells grown for 3 days in oestrogen-free medium, then treated with either 10 nM 17b-estradiol (E2) or a vehicle control for 6 h. Lysates were immunoprecipitated with antibodies to either ERa (6F11) or p68 (PAb204) and analysed by western blotting for ERa (HC20), p68 (2907) and p72 (DRD K12). The doublet observed in the p72 western blot shows the p72 and p82 isoforms of p72, which have been reported previously (Uhlmann-Schiffler et al., 2002; Ogilvie et al., 2003) .
p72 expression is associated with better prognosis in breast cancer To assess their significance in breast cancer pathogenesis, immunohistochemical staining of 233 ERa-positive tumours was performed for p68 and p72 (Figure 5a ). p68 and p72 staining data were obtained for 226 and 229 cases, respectively, of which 67 were p68 positive, and 173 were p72 positive. These tumours had previously been immunostained for ERa phosphorylated at S118, as well as a series of other markers including Her2, PR (Sarwar et al., 2006) and AIB-1. We correlated the expression of p68, p72 and these markers with other pathological and clinical data for each tumour, including histological grade, lymph node involvement, time to relapse and death (Table 1) . There was no statistically significant association between p68 and p72 expression in this group of patients (P ¼ 0.397). p68 expression was associated with Her2 and AIB-1 positivity (P ¼ 0.001 and Po0.001, respectively), as well as with increasing tumour grade (P ¼ 0.044), all of which are markers of poor prognosis (Osborne et al., 2003) . However, no association was identified between p68 expression and either relapse-free or overall survival (P ¼ 0.097 and 0.200 respectively) in our patient cohort (Figures 5b Figure 3 Short interfering RNA (siRNA)-mediated knockdown of p68 and p72 indicates that p72 is required for the expression of oestrogen-regulated genes. MCF-7 cells were grown in oestrogen-free medium for 72 h and then transfected using siRNAs against p68 or p72, or a non-silencing control (NS). After 56 h transfection, the cells were treated with 10 nM 17b-estradiol (E2) or an equivalent volume of ethanol for 16 h and then harvested for RNA or protein. cDNA prepared from these cells was used to carry out Taqman quantitative reverse transcription-PCR to examine the expression of the endogenous oestrogen-responsive genes pS2 (a) and cathepsin D (b), and western blotting was used to examine the expression of these genes at the protein level, with actin as a loading control (e). All graphs (a-d) are the means of three independent experiments±s.e.m.
p68, p72, ERa co-activation and breast cancer NC Wortham et al and c). Conversely, p72 expression was associated with a favourable prognosis. Most strikingly, p72-positive tumours were associated with Her2 negativity (P ¼ 0.008), progesterone receptor positivity (P ¼ 0.037) and reduced likelihood of relapse (P ¼ 0.025) and cancer death (P ¼ 0.014). In agreement with this, KaplanMeier analysis showed that p72-positive tumours are associated with a longer relapse-free period and overall survival (P ¼ 0.006 and 0.016 respectively) (Figures 5d  and e) . However, multivariate analysis showed that p72 was not a significant predictor of relapse-free or overall survival (Table 2) . Lymph node positivity, as well as Her2 and AIB1 expression were significant predictors of relapse-free survival (Po0.001, P ¼ 0.003 and 0.024, respectively), although lymph node positivity, Her2 positivity and tumour grade predicted overall survival (P ¼ 0.001, 0.017 and 0.008, respectively). Dysregulation of ERa-mediated inhibition of Her2 expression is one mechanism through which breast tumours may become resistant to anti-oestrogen treatment. AIB-1 is thought to have a crucial role in this dysregulation by competing for ERa binding with Pax2 and reversing ERa-dependent repression of Her2 (Hurtado et al., 2008) . We examined the effects of expression of p72 in AIB-1-positive tumours and its relation to Her2 expression. As has been previously described in a number of studies (Osborne et al., 2003) , AIB-1 positivity in the tumours was associated with poorer prognosis (Figures 6a and b) . Although the expression of p72 had little effect on the prognosis of patients with AIB-1-negative tumours, p72 expression in AIB-1-positive tumours was associated with an increased period of relapse-free and overall survival (Figures 6c and d , P ¼ 0.003 and 0.043, respectively). Furthermore, the proportion of Her2-positive tumours was significantly lower in AIB-1-positive tumours that were also positive for p72 (P ¼ 0.005, Figure 6e ). Expression of p68 did not show any association with prognosis in AIB-1-positive tumours, although the proportion of Her2-positive tumours was significantly increased in AIB-1-positive tumours expressing p68 (P ¼ 0.005), nor did p72 expression influence the prognosis of Her2-positive tumours ( Supplementary  Figures 2 and 3) .
Discussion
Recent studies have shown that the related p68 and p72 RNA helicases regulate gene expression by acting as Figure 4 Small interfering RNA (siRNA)-mediated knockdown of p72, but not p68, results in a slowdown of oestrogen-dependent growth of breast cancer cells. MCF-7 cells were grown for 3 days in oestrogen-free medium, then transfected with siRNAs against p68 or p72, or a non-silencing control (NS), in the presence or absence of 10 nM 17b-estradiol (E2) and/or 100 nM 4-hydroxytamoxifen (4-OHT). Cells were trypsinized and counted 4 days after transfection to assess cell growth. (a) Effect of p68 knockdown; (b) Effect of p72 knockdown; (c) Effect of p72 knockdown on growth in the presence of E2, 4-OHT or a combination of both ligands. Western blots showing knockdown of p68 and p72 at the time of counting accompany each graph. Cell counts are shown as relative to the untreated non-silencing control. Each count was carried out in triplicate within each experiment, and results are shown as the mean ± s.e.m. of at least three independent experiments. In all western blots, actin was used as a loading control.
p68, p72, ERa co-activation and breast cancer NC Wortham et al transcriptional co-regulators for diverse transcription factors (Fuller-Pace, 2006) . The first evidence for a role in gene regulation for p68 and p72 was reported for ERa, where p68 was identified on the basis of a preferential association with ERa phosphorylated at S118 in the transcription activation function AF1 (Endoh et al., 1999) . Subsequently, p72 was also shown to co-activate ERa (Watanabe et al., 2001) . In this study, we have undertaken a study of the importance of p68 and p72 in oestrogen-regulated gene expression in the ERa-positive and oestrogen-dependent MCF-7 cells. Our findings indicate that, although both proteins can act as ERa co-activators, p72 appears to have a more critical role in oestrogen signalling than p68.
In agreement with previous reports, both p68 and p72 act as ERa co-activators in a reporter gene assay, in a manner that is independent of p68 and p72 ATPase and p68, p72, ERa co-activation and breast cancer NC Wortham et al helicase activity. This implies that the N-and C-terminal regions of these proteins are important for co-activation and is consistent with our previous work, which also showed that these regions are critical for transcriptional regulation (Wilson et al., 2004) . Furthermore, although ser-118 is important for co-activation by p68 and p72 when assessing ERa lacking the ligand-binding domain/ AF2, another region, most likely the ERa DBD, is also important for interaction with p68/p72. Surprisingly, siRNA-mediated knockdown of p68 and p72 showed that although p72 is important for the regulation of oestrogen-responsive genes and for the oestrogen-stimulated growth of cells, p68 does not appear to be required. In contrast, immunohistochemical staining showed that p68 positivity is associated with markers of poor prognosis in ERa-positive breast cancer, suggesting that p68 and p72 may in fact have distinct roles in the regulation of ERa activity in breast cancer cells.
Investigation of the expression of p68 and p72 in a panel of breast cancers revealed that increased p72 expression is associated with a favourable prognosis. Patients whose cancers were p72 positive had a significantly increased period of disease-free and overall survival. However, p72 was not itself an independent predictor of patient outcome. The implication from our data is that p72 is required for oestrogen-dependent cell growth. Therefore, tumours expressing p72 are likely to be oestrogen sensitive, and so treatment with endocrine agents may be more effective in these patients. As the tumours in our cohort were all ERa positive, we were unable to ascertain whether a relationship between ERa and p72 expression exists. However, meta-analysis of publicly available data sets in Oncomine (Rhodes et al., Figure 6 Expression of p72 in AIB-1-positive tumours is associated with Her2 negativity and improved patient prognosis. AIB-1 expression is associated with shorter relapse-free (a) and overall survival (b) in our patient cohort. However, in AIB-1-positive patients, p72 positivity is associated with a longer relapse-free period (c) and overall survival (d). The proportion of Her2-positive tumours is significantly less in AIB-1-positive tumours expressing p72 than in those that were p72 negative (e). Table 1 ), which supports the hypothesis that p72 is required for oestrogen signalling.
A significantly greater proportion of p72-negative tumours were positive for Her2, which is associated with poor response to endocrine treatment in ERa-positive tumours (Osborne et al., 2003) . Interestingly, AIB-1, another marker of endocrine resistance and poor prognosis (Osborne et al., 2003) , did not correlate with p72 expression. Overexpression of AIB-1, usually through amplification of 20q13 (Anzick et al., 1997) , is thought to override ERa-mediated repression of Her2 by competing out Pax2 (Hurtado et al., 2008) . As would be expected, AIB-1 and Her2 expression are strongly correlated in our data set (P ¼ 0.002, data not shown). However, we found that in AIB-1-positive tumours the presence of p72 is associated with lower Her2 positivity compared with the p72-negative AIB1-positive tumours, which is suggestive of a role for p72 in ERa-mediated repression of Her2 expression. The role of p68 in breast cancer is less clear. Although p68 positivity appears to have no overall effect on survival, there is a strong association between the presence of p68 and markers of poor prognosis, in particular Her2 and AIB-1.
In summary, our data provide evidence for distinct roles for p68 and p72 in regulating ERa activity. Furthermore, we have shown that p72 is important for transcriptional regulation by ERa and oestrogen-dependent cell growth in breast cancer cells. Finally, immunohistochemical staining indicates that p72 is a marker of good prognosis in breast cancer.
Materials and methods
Cell maintenance MCF-7, ZR75-1 and COS-1 cells were routinely maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 2mM L-glutamine, 100 mg/ml streptomycin and 100 U/ml penicillin (all supplied by Invitrogen, Paisley, UK) in 5% CO 2 at 37 1C. Before transfection, cells were placed for 72 h in Dulbecco's modified Eagle's medium without phenol red (Invitrogen) supplemented with 5% double dextran-coated charcoalstripped fetal calf serum (First Link, Birmingham, UK), 2 mM glutamine, 100 mg/ml streptomycin and 100 U/ml penicillin.
Plasmids
Plasmids expressing full-length and deletion mutants of ERa have previously been described (Tora et al., 1989) , as have the GST-ERa fusion proteins and the oestrogen-responsive luciferase reporter gene (Lopez-Garcia et al., 2006) . p68, p72 and the DEAD-box mutants have also previously been described (Bates et al., 2005) . The SRC-1 expression plasmid was a kind gift of Professor M Parker. pERE3-TATA-luc has also previosuly been described (Thomas et al. 2008) . A thymidine kinase promoter Renilla luciferase reporter plasmid (RLTK; Promega, Madison, WI, USA) was used to control for transfection efficiency.
siRNA transfection Small interfering RNA transfections were carried out using Lipofectamine RNAiMax (Invitrogen) by reverse transfection. siRNA oligos against p68, p72 and a non-silencing control have been previously described (Bates et al., 2005) . 17-estradiol (Sigma-Aldrich, Poole, UK) was added to a final concentration of 10 nM, 56 h following transfection, and cells were harvested after a further 16 h for RNA or protein preparation. An equal volume of ethanol (vehicle) was added to the 'no ligand' controls.
Reporter gene assays COS-1 cells were transiently transfected with ERa or ERa deletion constructs, together with p68, p72, SRC1, together with pERE3-TAT-luc and pRL-TK reporter genes, as previously described (Thomas et al., 2008) . Luciferase activities were determined using Dual-Glo reagents (Promega). Firefly luciferase levels were corrected for transfection efficiency using corresponding renilla luciferase levels. All experiments were independently repeated at least three times, and the data graphed as mean values, with error bars representing the s.e.s of the mean.
GST-pulldown assay
Glutathione S-transferases-tagged proteins were expressed in Rosetta BL21 Escherichia coli cells and purified on glutathione beads (GE Healthcare, Little Chalfont, Buckinghamshire, UK) as previously described (Bates et al., 2005) . p68 and p72 were translated and 35 S-labelled using the TNT in vitro transcription/translation kit (Promega). The GST pull-down of in vitro-translated protein was carried out as described by Hsieh et al. (1999) . Where GST-tagged proteins were phosphorylated, the following modifications were made to the protocol. Following binding of GST lysates, the beads were washed and resuspended in 2.5 bed volumes of 1 Â MAPK buffer (New England Biolabs, Ipswich, MA, USA), containing 200 mM adenosine triphosphate. A volume of 0.5 ml per 30 ml of buffer of activated ERK2 (New England Biolabs) was added to the beads, which were then incubated at 30 1C for 30 min. Following this, the beads were washed and the protocol proceeded with incubation with 35 S-labelled proteins as previously described (Hsieh et al., 1999) .
Nuclear extract preparation and co-immunoprecipitation Nuclear extracts were prepared as described previously (Bates et al., 2005) from MCF-7 cells grown in oestrogen-depleted media (Dulbecco's modified Eagle's medium containing 5% dextran-coated charcoal-stripped fetal calf serum) for 72 h with the addition of 10 nM 17b-estradiol or an equivalent volume of ethanol for 6 h, before extract preparation. Immunoprecipitations were carried out using antibodies against ERa (6F11; Novocastra, Newcastle-upon-Tyne, UK) and p68 (PAb204; Millipore, Temecula, CA, USA) as described previously (Bates et al., 2005) .
Western blot analysis
Western blot analysis was carried out as described previously (Bates et al., 2005) using antibodies against p68 (PAb204 and 2907 (rabbit polyclonal raised against the C-terminal 15 amino acids of p68)); p72 (DRD-K12 (rabbit polyclonal raised against amino acids 12-26 of p72)); ERa (HC20; Santa Cruz Biotechnologies, Santa Cruz, CA, USA); ERa-phospho-S118 (Cell Signalling Technology, Danvers, MA, USA); pS2 (FL-84, Santa Cruz Biotechnologies); cathepsin D (D-19; Abcam, Cambridge, UK); and actin (A2066; Sigma-Aldrich). Appropriate horseradish peroxidase-conjugated anti-mouse and anti-rabbit secondary antibodies for immunoblotting were purchased from DAKO (Ely, UK).
